These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 19301897

  • 1. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH, Peng YH, Coumar MS, Chittimalla SK, Liao CC, Lyn PC, Huang CC, Lien TW, Lin WH, Hsu JT, Cheng JH, Chen X, Wu JS, Chao YS, Lee HJ, Juo CG, Wu SY, Hsieh HP.
    J Med Chem; 2009 Apr 23; 52(8):2618-22. PubMed ID: 19301897
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S, Okada K, Kiyota K, Isogai S, Iwago M, Shinozaki T, Kitamura Y, Kohno Y, Murakami K.
    J Med Chem; 2010 Jul 08; 53(13):5012-24. PubMed ID: 20527969
    [Abstract] [Full Text] [Related]

  • 3. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
    Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1617-22. PubMed ID: 18255290
    [Abstract] [Full Text] [Related]

  • 4. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O, Syha Y, Zettl H, Kock M, Bock A, Schubert-Zsilavecz M.
    Arch Pharm (Weinheim); 2008 Mar 01; 341(3):191-5. PubMed ID: 18275039
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
    Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, Wang P, Chao YS, Forrest M, Heck JV, Moller DE, Jones AB.
    J Med Chem; 2005 Jun 30; 48(13):4457-68. PubMed ID: 15974597
    [Abstract] [Full Text] [Related]

  • 6. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
    Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC.
    Bioorg Med Chem Lett; 2009 May 15; 19(10):2683-7. PubMed ID: 19376700
    [Abstract] [Full Text] [Related]

  • 7. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R, Zhou YL, Huan Y, Liu Q, Shen ZF, Liu ZZ.
    Yao Xue Xue Bao; 2011 Mar 15; 46(3):311-6. PubMed ID: 21626786
    [Abstract] [Full Text] [Related]

  • 8. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS, Bailey S, Almaden JV, Barnum SJ, Carlson TJ, Christie LC, Do QQ, Fraser JD, Hess M, Kellum J, Kim YH, McClellan GA, Ogilvie KM, Simmons BH, Skalitzky D, Sun S, Wilhite D, Zehnder LR.
    Bioorg Med Chem Lett; 2006 Dec 01; 16(23):6120-3. PubMed ID: 16973358
    [Abstract] [Full Text] [Related]

  • 9. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
    Popescu L, Rau O, Böttcher J, Syha Y, Schubert-Zsilavecz M.
    Arch Pharm (Weinheim); 2007 Jul 01; 340(7):367-71. PubMed ID: 17610302
    [Abstract] [Full Text] [Related]

  • 10. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH, Coumar MS, Leou JS, Wu JS, Shiao HY, Lin CH, Lin WH, Lien TW, Chen X, Hsu JT, Chao YS, Huang CF, Lyu PC, Hsieh HP, Wu SY.
    ChemMedChem; 2010 Oct 04; 5(10):1707-16. PubMed ID: 20734309
    [Abstract] [Full Text] [Related]

  • 11. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.
    J Med Chem; 2011 Dec 22; 54(24):8541-54. PubMed ID: 22070604
    [Abstract] [Full Text] [Related]

  • 12. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A, Gavande N, Kim MS, Yang NX, Salam NK, Hanrahan JR, Roubin RH, Hibbs DE.
    J Med Chem; 2009 Nov 12; 52(21):6835-50. PubMed ID: 19807106
    [Abstract] [Full Text] [Related]

  • 13. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
    Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Märki HP, Meyer M, Mohr P.
    Bioorg Med Chem Lett; 2006 Aug 01; 16(15):4016-20. PubMed ID: 16737814
    [Abstract] [Full Text] [Related]

  • 14. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
    Zaware P, Shah SR, Pingali H, Makadia P, Thube B, Pola S, Patel D, Priyadarshini P, Suthar D, Shah M, Jamili J, Sairam KV, Giri S, Patel L, Patel H, Sudani H, Patel H, Jain M, Patel P, Bahekar R.
    Bioorg Med Chem Lett; 2011 Jan 15; 21(2):628-32. PubMed ID: 21195611
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG, Kim NJ, Koo BW, Lee KO, Moon SH, Shin DH, Jung JW, Paek SM, Chang DJ, Li F, Kang HJ, Le TV, Chae YN, Shin CY, Kim MK, Lim JI, Ryu JS, Park HJ.
    J Med Chem; 2008 Oct 23; 51(20):6318-33. PubMed ID: 18826205
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K.
    Bioorg Med Chem; 2006 Jan 01; 14(1):98-108. PubMed ID: 16198578
    [Abstract] [Full Text] [Related]

  • 17. Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
    Devasthale PV, Chen S, Jeon Y, Qu F, Ryono DE, Wang W, Zhang H, Cheng L, Farrelly D, Golla R, Grover G, Ma Z, Moore L, Seethala R, Sun W, Doweyko AM, Chandrasena G, Sleph P, Hariharan N, Cheng PT.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2312-6. PubMed ID: 17292606
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS, Almaden JV, Barnum SJ, Carlson TJ, Do QQ, Fraser JD, Hess M, Kim YH, Ogilvie KM, Sun S.
    Bioorg Med Chem Lett; 2006 Dec 01; 16(23):6116-9. PubMed ID: 16979341
    [Abstract] [Full Text] [Related]

  • 20. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 01; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.